Get the Stockscreener App
25.93
2.90%
0.73
After Hours:
25.90
-0.03
-0.12%
Maze Therapeutics Inc stock is traded at $25.93, with a volume of 479.84K.
It is up +2.90% in the last 24 hours and up +78.95% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$25.20
Open:
$25.2
24h Volume:
479.84K
Relative Volume:
1.19
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.22%
1M Performance:
+78.95%
6M Performance:
+135.51%
1Y Performance:
+0.00%
1-Day Range:
$24.42
$26.45
1-Week Range:
$24.42
$28.37
52-Week Range:
$6.71
$28.37
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
25.93 | 1.11B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
Detecting price anomalies in Maze Therapeutics Inc. with AIJuly 2025 Rallies & Community Supported Trade Ideas - newser.com
Predicting Maze Therapeutics Inc. trend using moving averagesJuly 2025 Sector Moves & Short-Term High Return Ideas - newser.com
Goldman Sachs Group Inc. Makes New $145,000 Investment in Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.2%Should You Sell? - MarketBeat
What technical models suggest about Maze Therapeutics Inc.’s comebackDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Developing predictive dashboards with Maze Therapeutics Inc. dataJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
What drives Maze Therapeutics Inc stock priceAnalyst Downgrades & High Yield Trading Growth - earlytimes.in
What analysts say about Maze Therapeutics Inc stockEarnings Beat Highlights & Outstanding Trading Tips - earlytimes.in
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.4%Still a Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Reaches New 52-Week HighHere's Why - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $32.67 Average PT from Analysts - Defense World
How hedge fund analytics apply to Maze Therapeutics Inc. stock2025 Institutional Moves & Weekly Top Performers Watchlists - newser.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
HC Wainwright Reaffirms Buy Rating for Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Analyzing Maze Therapeutics (NASDAQ:MAZE) and Syndax Pharmaceuticals (NASDAQ:SNDX) - Defense World
Institution Moves: What’s the fair value of Maze Therapeutics Inc. stock2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Candlestick signals on Maze Therapeutics Inc. stock todayTrade Performance Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Maze Therapeutics (NASDAQ:MAZE) Director Sells $464,043.28 in Stock - MarketBeat
Maze Therapeutics Inc. stock trend outlook and recovery pathNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com
Market reaction to Maze Therapeutics Inc.’s recent newsIPO Watch & Community Driven Trade Alerts - newser.com
Will Maze Therapeutics Inc. rebound enough to break even2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Maze Therapeutics, Inc. (MAZE): A Bull Case Theory - Insider Monkey
Maze Therapeutics (NASDAQ:MAZE) Receives “Buy” Rating from HC Wainwright - Defense World
Can Maze Therapeutics Inc. recover in the next quarterQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Biotech Breakouts: 3 Stocks With Massive Upside Potential - Investing.com
Tools to monitor Maze Therapeutics Inc. recovery probability2025 Support & Resistance & Safe Entry Zone Tips - newser.com
Analyzing drawdowns of Maze Therapeutics Inc. with statistical toolsJuly 2025 Summary & Proven Capital Preservation Methods - newser.com
Biotech Breakouts: 3 Stocks With Massive Upside Potential - sharewise.com
Maze Therapeutics (NASDAQ:MAZE) Shares Gap DownHere's Why - MarketBeat
Maze Therapeutics director Scheller sells $464k in shares By Investing.com - Investing.com Australia
New Options Available for Maze Therapeutics (MAZE) - GuruFocus
Quarterly Recap: Will COOT outperform tech stocks2025 Valuation Update & Consistent Growth Stock Picks - خودرو بانک
Maze Therapeutics Director Cashes Out in Major Stock Sale! - TipRanks
Maze Therapeutics Inc. stock daily chart insightsQuarterly Portfolio Summary & Community Verified Watchlist Alerts - newser.com
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):